3-[4-(3,4-Dimethoxy-benzenesulfonylamino)-phenyl]-acrylic acid | 501682-95-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 3-[4-(3,4-Dimethoxy-benzenesulfonylamino)-phenyl]-acrylic acid
• 英文别名: (E)-3-[4-[(3,4-dimethoxyphenyl)sulfonylamino]phenyl]prop-2-enoic acid
• CAS: 501682-95-7
• 化学式: C₁₇H₁₇NO₆S
• 分子量: 363.391
• InChiKey: PNTBEODZAXNDGM-BJMVGYQFSA-N

物化性质

• 沸点：
  568.1±60.0 °C(Predicted)
• 密度：
  1.386±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  110
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  3-[4-(3,4-Dimethoxy-benzenesulfonylamino)-phenyl]-acrylic acid 在 甲醇 、 D(+)-10-樟脑磺酸 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 (2E)-3-{4-{[(3,4-dimethoxyphenyl)sulfonyl]amino}phenyl}-N-hydroxyprop-2-enamide
  参考文献：
  名称：

  开发潜在的抗肿瘤药物。一套新的磺酰胺衍生物作为组蛋白脱乙酰基酶抑制剂的合成和生物学评估。

  摘要：

  作为组蛋白脱乙酰基酶（HDAC）抑制剂，已经合成并研究了一系列磺酰胺异羟肟酸和苯甲酸酯，它们可以诱导人癌细胞中组蛋白的超乙酰化。HDAC活性的抑制代表一种干预细胞周期调控的新方法。在一组人类肿瘤和正常细胞系中筛选了主要候选药物。它们选择性抑制增殖，引起细胞周期阻滞，并诱导人癌细胞而非正常细胞凋亡。描述了结构活性关系，抗增殖活性和体内功效。

  DOI：

  10.1021/jm020377a
• 作为产物：
  描述：

  3,4-二甲氧基苯磺酰氯 在 Pd-EnCat^TM N-(methylpolystyrene)-4-(methylamino)pyridine 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 21.0h， 生成 3-[4-(3,4-Dimethoxy-benzenesulfonylamino)-phenyl]-acrylic acid
  参考文献：
  名称：

  Polymer-assisted, multi-step solution phase synthesis and biological screening of histone deacetylase inhibitors

  摘要：

  本文介绍了通过聚合物辅助溶液相合成（PASP）制备一系列组蛋白去乙酰化酶（HDAc）抑制剂的方法。HDAc抑制剂具有相当大的潜力作为新型抗增殖剂。选定的化合物被证明能抑制人体内皮细胞增殖和体外血管生成模型中管状结构（新血管形成）的形成。

  DOI：

  10.1039/b313414h

文献信息

• Development of Potential Antitumor Agents. Synthesis and Biological Evaluation of a New Set of Sulfonamide Derivatives as Histone Deacetylase Inhibitors
  作者：Giliane Bouchain、Silvana Leit、Sylvie Frechette、Elie Abou Khalil、Rico Lavoie、Oscar Moradei、Soon Hyung Woo、Marielle Fournel、Pu T. Yan、Ann Kalita、Marie-Claude Trachy-Bourget、Carole Beaulieu、Zuomei Li、Marie-France Robert、A. Robert MacLeod、Jeffrey M. Besterman、Daniel Delorme

  DOI：10.1021/jm020377a

  日期：2003.2.1

  and anilides have been synthesized and studied as histone deacetylase (HDAC) inhibitors that can induce hyperacetylation of histones in human cancer cells. The inhibition of HDAC activity represents a novel approach for intervening in cell cycle regulation. The lead candidates were screened in a panel of human tumor and normal cell lines. They selectively inhibit proliferation, cause cell cycle blocks

  作为组蛋白脱乙酰基酶（HDAC）抑制剂，已经合成并研究了一系列磺酰胺异羟肟酸和苯甲酸酯，它们可以诱导人癌细胞中组蛋白的超乙酰化。HDAC活性的抑制代表一种干预细胞周期调控的新方法。在一组人类肿瘤和正常细胞系中筛选了主要候选药物。它们选择性抑制增殖，引起细胞周期阻滞，并诱导人癌细胞而非正常细胞凋亡。描述了结构活性关系，抗增殖活性和体内功效。
• Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
  申请人：——

  公开号：US20040077726A1

  公开（公告）日：2004-04-22

  This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula: (I) A is an aryl group; Q1 is a covalent bond or an aryl leader group; J is a sulfonamide linkage selected from: —S (═O)2NR1— and —NR1S(═O)2—; R1 is a sulfonamido substituent; and, Q2 is an acid leader group; with the proviso that if J is —S(═O)2NR1—, then Q1 is an aryl leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis.

  这项发明涉及抑制HDAC活性的某些活性碳酸酯化合物，其化学式如下：(I) A为芳基；Q1为共价键或芳基引导基团；J为从以下选取的磺胺酰胺连接：—S(═O)2NR1—和—NR1S(═O)2—；R1为磺胺基取代基；Q2为酸引导基团；但条件是如果J为—S(═O)2NR1—，则Q1为芳基引导基团；以及其药学上可接受的盐、溶剂化合物、酰胺、酯、醚、化学保护形式和前药。本发明还涉及包含这种化合物的药物组合物，以及在体内外使用这种化合物和组合物来抑制HDAC，例如抑制增殖性疾病，如癌症和牛皮癣。
• [EN] CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS<br/>[FR] COMPOSES D'ACIDE CARBAMIQUE COMPRENANT UNE LIAISON SULFONAMIDE EN TANT QU'INHIBITEURS DE HDAC
  申请人：PROLIFIX LTD

  公开号：WO2002030879A2

  公开（公告）日：2002-04-18

  This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula: (I) A is an aryl group; Q1 is a covalent bond or an aryl leader group; J is a sulfonamide linkage selected from: -S(=O)¿2NR?1- and -NR1S(=O)2-; R1 is a sulfonamido substituent; and, Q2 is an acid leader group; with the proviso that if J is -S(=O)¿2NR?1-, then Q1 is an aryl leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis.

  本发明涉及某些活性碳酰胺类化合物，其抑制HDAC活性，并具有以下式子：（I）其中，A是芳基基团；Q1是共价键或芳基领导基团；J是从-S（=O）2NR1-和-NR1S（=O）2-中选择的磺酰胺键；R1是磺酰胺基取代基；Q2是酸领导基团；前提是如果J是-S（=O）2NR1-，则Q1是芳基领导基团；以及其药学上可接受的盐，溶剂化物，酰胺，酯，醚，化学保护形式和前药。本发明还涉及包含此类化合物的药物组合物以及使用这些化合物和组合物，无论是体外还是体内，来抑制HDAC，例如抑制增殖性疾病，如癌症和牛皮癣。
• Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
  申请人：Watkins J. Clare

  公开号：US20050085515A1

  公开（公告）日：2005-04-21

  This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula: (I) A is an aryl group; Q 1 is a covalent bond or an aryl leader group; J is a sulfonamide linkage selected from: —S(═O) 2 NR 1 — and —NR 1 S(═O) 2 —; R 1 is a sulfonamido substituent; and, Q 2 is an acid leader group; with the proviso that if J is —S(═O) 2 NR 1 —, then Q 1 is an aryl leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis.

  本发明涉及某些活性的碳酰胺酸化合物，其抑制HDAC活性，其化学式为：（I）其中，A是芳基基团；Q1是共价键或芳基领导基团；J是从以下选择的磺酰胺键链：—S（═O）2NR1—和—NR1S（═O）2—；R1是磺酰胺取代基；Q2是酸领导基团；但是，如果J是—S（═O）2NR1—，则Q1是芳基领导基团；以及其药学上可接受的盐、溶剂化物、酰胺、酯、醚、化学保护形式和前药。本发明还涉及包含这种化合物的制药组合物，以及使用这种化合物和组合物，在体内外抑制HDAC，例如抑制增生状况，如癌症和牛皮癣。
• CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS
  申请人：Watkins Clare J.

  公开号：US20080161401A1

  公开（公告）日：2008-07-03

  This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula: (I) A is an aryl group; Q 1 is a covalent bond or an aryl leader group; J is a sulfonamide linkage selected from: —S(═O) 2 NR 1 — and —NR 1 S(═O) 2 —; R 1 is a sulfonamido substituent; and, Q 2 is an acid leader group; with the proviso that if J is —S(═O) 2 NR 1 —, then Q 1 is an aryl leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis.

  本发明涉及某些活性碳酰胺酸化合物，其抑制HDAC活性，具有以下公式：（I）其中，A是芳基基团；Q1是共价键或芳基引导基团；J是从以下选择的磺酰胺键连接：—S（═O）2NR1—和—NR1S（═O）2—；R1是磺酰胺取代基；Q2是酸引导基团；但是，如果J是—S（═O）2NR1—，则Q1是芳基引导基团；以及其药学上可接受的盐，溶剂化合物，酰胺，酯，醚，化学保护形式和前药。本发明还涉及包含这种化合物的制药组合物，以及在体内外使用这种化合物和组合物来抑制HDAC，例如，抑制增殖性疾病，如癌症和牛皮癣。